770 related articles for article (PubMed ID: 35650613)
1. Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.
Alajangi HK; Kaur M; Sharma A; Rana S; Thakur S; Chatterjee M; Singla N; Jaiswal PK; Singh G; Barnwal RP
Mol Brain; 2022 Jun; 15(1):49. PubMed ID: 35650613
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
3. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
Bagchi S; Chhibber T; Lahooti B; Verma A; Borse V; Jayant RD
Drug Des Devel Ther; 2019; 13():3591-3605. PubMed ID: 31695329
[TBL] [Abstract][Full Text] [Related]
4. Strategies for transporting nanoparticles across the blood-brain barrier.
Zhang TT; Li W; Meng G; Wang P; Liao W
Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
[TBL] [Abstract][Full Text] [Related]
5. Experimental methods and transport models for drug delivery across the blood-brain barrier.
Fu BM
Curr Pharm Biotechnol; 2012 Jun; 13(7):1346-59. PubMed ID: 22201587
[TBL] [Abstract][Full Text] [Related]
6. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.
Vlieghe P; Khrestchatisky M
Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495
[TBL] [Abstract][Full Text] [Related]
7. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
[TBL] [Abstract][Full Text] [Related]
8. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.
Biddlestone-Thorpe L; Marchi N; Guo K; Ghosh C; Janigro D; Valerie K; Yang H
Adv Drug Deliv Rev; 2012 May; 64(7):605-13. PubMed ID: 22178615
[TBL] [Abstract][Full Text] [Related]
9. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
Zhou X; Smith QR; Liu X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
[TBL] [Abstract][Full Text] [Related]
10. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
Al-Ahmady ZS
Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
[TBL] [Abstract][Full Text] [Related]
11. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier.
Sharma G; Sharma AR; Lee SS; Bhattacharya M; Nam JS; Chakraborty C
Int J Pharm; 2019 Mar; 559():360-372. PubMed ID: 30721725
[TBL] [Abstract][Full Text] [Related]
12. Transcellular brain drug delivery: A review on recent advancements.
Azarmi M; Maleki H; Nikkam N; Malekinejad H
Int J Pharm; 2020 Aug; 586():119582. PubMed ID: 32599130
[TBL] [Abstract][Full Text] [Related]
13. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.
Patel MM; Patel BM
CNS Drugs; 2017 Feb; 31(2):109-133. PubMed ID: 28101766
[TBL] [Abstract][Full Text] [Related]
14. Applications of nanotechnology in drug delivery to the central nervous system.
Saeedi M; Eslamifar M; Khezri K; Dizaj SM
Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
[TBL] [Abstract][Full Text] [Related]
15. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
Sa P; Singh P; Dilnawaz F; Sahoo SK
Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
[TBL] [Abstract][Full Text] [Related]
16. CNS drug delivery systems: novel approaches.
Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
[TBL] [Abstract][Full Text] [Related]
17. New experimental models of the blood-brain barrier for CNS drug discovery.
Kaisar MA; Sajja RK; Prasad S; Abhyankar VV; Liles T; Cucullo L
Expert Opin Drug Discov; 2017 Jan; 12(1):89-103. PubMed ID: 27782770
[TBL] [Abstract][Full Text] [Related]
18. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
19. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J; Agrahari V; Youm I
J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
[TBL] [Abstract][Full Text] [Related]
20. Dendrimer advances for the central nervous system delivery of therapeutics.
Xu L; Zhang H; Wu Y
ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
